University of California, Los Angeles (UCLA) at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

University of California, Los Angeles (UCLA) takes part in 5 sessions at ESMO 2026 in Madrid. Its program spans targeted immunotherapy with PD-1 blockade and new drug results in breast, pancreatic, gastric and germ cell cancers. Highlights include a RAS inhibitor compared with chemotherapy in previously treated metastatic pancreatic cancer, and six-year survival for adjuvant ribociclib in hormone receptor-positive, HER2-negative early breast cancer.

OrganizationESMO 2026 Attendance
ucla.edu
University & institute
Public research university in Los Angeles, California, with a school of medicine and an NCI-designated comprehensive cancer centre.
Keynote
Fri Oct 23
12:18–12:28
Abstract
Fri Oct 23
13:35–13:40
1210RO - Safety and Efficacy of Ixotatug Vedotin (TORL-1-23), a Claudin 6-Targeted ADC, as Monotherapy in Germ Cell Tumors (GCT)
Rapid oral: Genitourinary tumours, prostate, penile and testils
Genitourinary cancersGastrointestinal cancers
Abstract
Fri Oct 23
14:22–14:32
Abstract
Fri Oct 23
14:25–14:35
Abstract
Fri Oct 23
17:19–17:24

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from University of California, Los Angeles (UCLA)

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction